TrialPath
Melanoma · Boston

Melanoma clinical trials in Boston

20 recruiting melanoma studies within range of Boston. Click any trial for full eligibility criteria and contact info.

The Cancer of the Pancreas Screening-5 CAPS5)Study

NCT02000089 · Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation
Recruiting

Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.

PhasePhase 3
TypeInterventional
Age18 Years
WhereNew Haven, Connecticut, United States + 8 more
SponsorJohns Hopkins University
▾Tap for details
Apply

High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial

NCT06298734 · Melanoma (Skin), Skin Cancer, Advanced Melanoma
Recruiting

The purpose of this study is to determine whether high-intensity exercise and high-fiber diet are feasible and improve various health outcomes among participants with advanced melanoma receiving immunotherapy. The names of the groups in this research study are: * High-Intensity Exercise (EX) * High-fiber Diet (DT) * Combined High-Intensity Exercise and High-Fiber Diet (COMB) * Attention Control (AC)

PhaseNA
TypeInterventional
Age18 Years
WhereBoston, Massachusetts, United States + 1 more
SponsorFred Hutchinson Cancer Center
▾Tap for details
Apply

Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver

NCT07364474 · Uveal Melanoma
Recruiting

This study seeks to better understand the liver's immune response to receiving chemotherapy agent melphalan through Percutaneous Hepatic Perfusion (PHP) alone or in combination with Ipilimumab and Nivolumab for patients with Uveal Melanoma that has metastasized to the liver.

PhaseNA
TypeInterventional
Age18 Years
WhereBoston, Massachusetts, United States
SponsorMassachusetts General Hospital
▾Tap for details
Apply

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

NCT04899908 · Brain Cancer, Brain Metastases, Melanoma
Recruiting

The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that are more difficult to control with stereotactic radiation alone.

PhasePhase 2
TypeInterventional
Age18 Years
WhereBoston, Massachusetts, United States + 1 more
SponsorBrigham and Women's Hospital
▾Tap for details
Apply

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

NCT05059444 · Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma
Recruiting

The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.

Phase—
TypeObservational
Age18 Years
WhereBirmingham, Alabama, United States + 56 more
SponsorGuardant Health, Inc.
▾Tap for details
Apply

Neurocutaneous Melanocytosis Registry

NCT04548817 · Cutaneous Melanocytic Neoplasm, Large Cutaneous Melanocytic Nevi, Neurocutaneous Melanocytosis
Recruiting

This study will involve collecting information about the regular medical care you receive for large cutaneous melanocytic nevi (LCMN) or neurocutaneous melanocytosis (NCM).

Phase—
TypeObservational
AgeAny
WhereBoston, Massachusetts, United States + 1 more
SponsorMemorial Sloan Kettering Cancer Center
▾Tap for details
Apply

ACTengine® IMA203 Combined With mRNA-4203

NCT06946225 · Cutaneous Melanoma, Synovial Sarcoma
Recruiting

This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).

PhasePhase 1
TypeInterventional
Age18 Years
WhereSan Francisco, California, United States + 3 more
SponsorImmatics US, Inc.
▾Tap for details
Apply

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

NCT05136196 · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Recruiting

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine how quickly patients can be divided into groups based on biomarkers in their tumors. A biomarker is a biological molecule found in the blood, other body fluids, or in tissues that is a sign of a normal or abnormal process or a sign of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. The two biomarkers that this trial is studying are "tumor mutational burden" and "tumor inflammation signature." Another purpose of this trial is to help doctors learn if cabozantinib and nivolumab shrink or stabilize the cancer, and whether patients respond differently to the combination depending on the status of the biomarkers.

PhasePhase 2
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 232 more
SponsorNational Cancer Institute (NCI)
▾Tap for details

Clonal Hematopoiesis Chemotherapy and Radiation Effects Study

NCT07675967 · Lung Cancer (Diagnosis), Osteochondroma, Spitz Nevus
Recruiting

The goal of the Clonal Hematopoiesis Chemotherapy and Radiation Effects (CH CARE) Study is to understand how the presence or absence of clonal hematopoiesis (CH) influences outcomes in people receiving chemotherapy and radiation for solid cancers. The study will collect biospecimens and clinical information. These data will be used to define clinical and molecular features that predict the presence of high-risk clonal hematopoiesis (CH) in patients exposed to cytotoxic anti-cancer therapy. Predictive features will be utilized to identify populations of cancer patients and survivors who are at the highest risk of developing therapy-related myeloid neoplasms (t-MNs). Ultimately this study will result in the development of a novel novel risk prediction algorithm for t-MNs in patients with solid cancers and drive potential therapeutic approaches to intercept progression from CH to often fatal t-MNs.

Phase—
TypeObservational
Age18 Years
WhereBoston, Massachusetts, United States
SponsorDana-Farber Cancer Institute
▾Tap for details
Apply

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

NCT05280314 · Melanoma, Squamous Cell Carcinoma of Head and Neck
Recruiting

This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indications.

PhasePhase 2
TypeInterventional
Age18 Years
WhereNew Haven, Connecticut, United States + 14 more
SponsorIO Biotech
▾Tap for details
Apply

Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

NCT07804186 · Uveal Melanoma
Recruiting

This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)

PhasePhase 3
TypeInterventional
Age18 Years
WhereScottsdale, Arizona, United States + 28 more
SponsorIDEAYA Biosciences
▾Tap for details
Apply

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

NCT04370587 · Solid Tumor, Melanoma, HNSCC
Recruiting

This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years
WhereGilbert, Arizona, United States + 8 more
SponsorImmVira Pharma Co. Ltd
▾Tap for details
Apply

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

NCT06425926 · Melanoma Stage IV, Solid Tumor
Recruiting

GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years
WhereScottsdale, Arizona, United States + 10 more
SponsorGeorgiamune Inc
▾Tap for details
Apply

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

NCT05592626 · Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms
Recruiting

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with advanced solid tumors that are antigen-rich.

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years
WhereSacramento, California, United States + 18 more
SponsorMarengo Therapeutics, Inc.
▾Tap for details
Apply

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

NCT05379985 · Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
Recruiting

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years
WhereOrange, California, United States + 20 more
SponsorRevolution Medicines, Inc.
▾Tap for details
Apply

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

NCT06112314 · Advanced Melanoma
Recruiting

This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma.

PhasePhase 3
TypeInterventional
Age18 Years
WhereTucson, Arizona, United States + 210 more
SponsorImmunocore Ltd
▾Tap for details
Apply

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Recruiting

The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.

PhasePhase 2 / Phase 3
TypeInterventional
AgeAny
WhereScottsdale, Arizona, United States + 32 more
SponsorReplimune, Inc.
▾Tap for details
Apply

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

NCT07749586 · Advanced Solid Tumor
Recruiting

This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors. This is an open-label study which means that participants and study staff will know that all participants will receive ARV-6723. The investigational drug ARV-6723 will be given as an oral tablet on its own and also in combination with other drugs. Researchers think that ARV-6723 can help the body's immune system to better recognize, attack, and destroy cancer cells in adults with advanced solid tumors. ARV-6723 is an investigational drug, and this is the first time ARV-6723 will be used in humans. Depending on the treatment assignment, the investigational drug, ARV-6723, will be given as an oral tablet either on its own (monotherapy) or in combination with pembrolizumab, either through a vein (intravenously or IV) or through an injection beneath the skin (subcutaneously or SQ). This study will include multiple parts: In Part A1 (Phase 1a), different small groups of participants will receive lower to higher doses of ARV-6723 as monotherapy or in combination with standard-dose of pembrolizumab. In Part A2 (Phase 1b), two groups of participants with specific tumor indication(s) (TBD) will receive one of two doses selected based on information from Part A1. Details of Part B will be determined based on information generated from Part A.

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years
WhereBoston, Massachusetts, United States + 4 more
SponsorArvinas Inc.
▾Tap for details
Apply

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

NCT05549297 · Advanced Melanoma
Recruiting

The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care \[SoC\], best supportive care \[BSC\] on protocol survivor follow up) in patients with advanced non-ocular melanoma.

PhasePhase 3
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 81 more
SponsorImmunocore Ltd
▾Tap for details
Apply

Neoadjuvant Darovasertib in Primary Uveal Melanoma

NCT07015190 · Uveal Melanoma
Recruiting

This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)

PhasePhase 3
TypeInterventional
Age18 Years
WhereScottsdale, Arizona, United States + 93 more
SponsorIDEAYA Biosciences
▾Tap for details
Apply